Journal of gastroenterology
-
Randomized Controlled Trial Clinical Trial
Bezafibrate treatment: a new medical approach for PBC patients?
A new medical approach to primary biliary cirrhosis (PBC) has been desired. We investigated the feasibility of using combination ursodeoxycholic acid (UDCA)-bezafibrate therapy in patients with PBC nonresponsive to UDCA monotherapy. ⋯ UDCA at 600 mg/day plus bezafibrate at 400 mg/day may be considered as a new therapeutic option for patients with PBC.